Status:
COMPLETED
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Nasopharyngeal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regi...
Detailed Description
Nasopharyngeal carcinoma (NPC) is most commonly seen in Southeast Asia, especially in southern and southeastern China ,where the incidence rate has been documented between 10 and 150 cases per 100,000...
Eligibility Criteria
Inclusion
- Histologically proven NPC diagnosis
- Elder than 18 years old are inclusive
- Recurrence or metastatic nasopharyngeal carcinoma with evidence of unsuitable for local treatment
- Amenable to regular follow-up
- Subjects with at least one measurable lesion (Tumor lesions that are situated in a previously irradiated area could not be considered measurable).
- Performance status: 0-1(ECOG)
- WBC \> 4.0X109/L, PLT \> 100X109/L, with normal hepatic function(AST, ALT \< 2.5 x upper limit of normal , and bilirubin \< 1.5 x upper limit of normal), with normal renal function (Creatinine \< 1.5 x upper limit of normal)
- No chemotherapy or radical radiotherapy received within 6 months prior to enrollment
- Life expectancy over twelve weeks
- Signed and dated informed consent before the start of specific protocol procedures
- Ability to comply with trial requirements.
Exclusion
- Patient suitable for local treatment (eg. radiotherapy)
- Active clinically serious infections (\> grade 2 NCI-CTC version 3.0)
- Patient with central nervous system metastasis
- Patient life threatening medical condition
- Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
- Performance status ≥ 2
- With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI CTC\] grade ≥ 2)
- Serious concurrent illness
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors\[Ta, Tis \& T1\] or any cancer curatively treated \> 3 years prior to study entry.
- Patient refusing participation
Key Trial Info
Start Date :
February 21 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2020
Estimated Enrollment :
362 Patients enrolled
Trial Details
Trial ID
NCT01528618
Start Date
February 21 2012
End Date
December 20 2020
Last Update
October 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510060